Managing UA/NSTEMI: A Rural Hospital Approach
Christopher P. Cannon, MD
Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Senior Physician, Cardiovascular Division
Brigham and Women's Hospital
Charles V. Pollack Jr, MA, MD, FACEP, FAAEM, FAHA
Professor of Emergency Medicine
University of Pennsylvania School of Medicine
Department of Emergency Medicine
Unstable angina and non-ST-segment elevation myocardial infarction, collectively known as UA/NSTEMI, is the most commonly-occuring form of acute coronary syndromes (ACS) and accounts for over one million hosptial discharges each year in the United States. Rural hospital teams have unique challenges in optimizing their resources to provide timely risk statification and treatment for patients present with UA/NSTEMI. In this video, a renowned cardiologist and distignuised emergency medicine specialist review key guideline recommendations along with practical advice for improving UA/NSTEMI patient care in the rural hospital setting. Quailty-improvement tools such as standing orders and discharge checklists are provided for download to help clinicians implement current guidelines in practice.
Method of Participation and Evaluation
To participate in this CME activity, please read the following information and click "Launch Program" at the bottom of this page. Complete the online evaluation at the conclusion of the activity. You may print your certificate immediately after completion of the evaluation. Please note: To view this program you need a computer with an Internet browser and audio and video capabilities.
Up to 0.5 AMA PRA Category 1 Credit™
This activity is designed for cardiologists, emergency medicine physicians, hospitalists, internists, and other healthcare professionals who have an interest in treating patients with acute coronary syndromes.
After taking part in this CME activity, participants should be able to:
- Utilize appropriate risk-score tools (eg, TIMI or GRACE) as supplement to clinical judgement in early risk stratification and assessment of patients with UA/NSTEMI
- Administer anithrombotic therapies based on appropriate dosing guidelines and the patient's risk of ischemic and bleeding complications
- Employ evidence-based admission and discharge checklists and order forms for assessing and managing patients with UA/NSTEMI
Christopher P. Cannon, MD, has served as a consultant to Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Novartis Pharmaceuticals Corporation, and Pfizer Inc; has received research support from Accumetrics, AstraZeneca Pharmaceuticals LP, Essentialis, Inc., GlaxoSmithKline, Merck & Co., Inc., and Takeda Pharmaceuticals North America, Inc.; and has indicated ownership interests in Automedics Medical Systems.
Charles Pollack, MA, MD, FACEP, FAAEM, FAHA, has served as a consultant to sanofi-aventis and Schering-Plough Corporation; and has received honoraria from sanofi-aventis.
The Foundation for Improving Patient Outcomes staff and the independent peer reviewer report no financial relationship with commercial interests.
CME Credit Designations
ACCME The Foundation for Improving Patient Outcomes (FFIPO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA FFIPO designates this educational activity for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AOA This activity is eligible for up to 0.5 hour of credit in Category 2-A of the American Osteopathic Association.